Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 7/20 | 0.56 |
| ▸ | TOP2A | P11388 | 6/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549234 | 0.83 | TOP2A (0.57) | NISCHTOP2ATOP2BALDH1A1CYP1A2 | |
| SCHEMBL8536014 | 0.81 | NISCH (0.58) | NISCHTOP2ATOP2BMAOAMAOB | |
| SCHEMBL7734244 | 0.76 | MAOB (0.47) | ALDH1A1MAOAMAOB | |
| SCHEMBL6465427 | 0.75 | NISCH (0.55) | NISCHALDH1A1CYP1A2MAOB | |
| SCHEMBL7732923 | 0.75 | AR (0.51) | ALDH1A1CASP1CASP7MAOB | |
| SCHEMBL1886692 | 0.75 | NISCH (1.00) | NISCHTOP2ATOP2BMAOAMAOB | |
| SCHEMBL14089880 | 0.73 | NISCH (0.79) | NISCHTOP2ATOP2BALDH1A1CYP1A2 | |
| SCHEMBL549282 | 0.72 | TOP2A (1.00) | NISCHTOP2ATOP2BALDH1A1CYP1A2 | |
| SCHEMBL8211455 | 0.70 | NISCH (0.65) | NISCHTOP2ATOP2BALDH1A1CYP1A2 | |
| SCHEMBL7735081 | 0.70 | PTGS1 (0.32) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| EP-0758453-A1 | METHOD OF FLUORESCENT DETECTION OF NUCLEIC ACIDS AND CYTOSKELETON ELEMENTS USING BIS-DICATIONIC ARYL FURANS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5602172-A | USING A 2,5-DIPHENYLFURAN COMPOUND | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-11 | — | — | US | disclosed |
| US-5594138-A | MEDICAL DIAGNOSIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996040997-A1 | METHOD OF FLUORESCENT DETECTION OF NUCLEIC ACIDS AND CYTOSKELETON ELEMENTS USING BIS-DICATIONIC ARYL FURANS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996015126-A1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1995030901-A1 | METHOD OF FLUORESCENT DETECTION OF NUCLEIC ACIDS AND CYTOSKELETON ELEMENTS USING BIS-DICATIONIC ARYL FURANS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | NISCH 967/4885TOP2A 59/4885TOP2B 104/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | NISCH 284/4885TOP2A 63/4885TOP2B 43/4885 |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | NISCH 3115/4885TOP2A 2285/4885TOP2B 2297/4885 |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | COL2A1, MMP1, FN1 | NISCH 59/4885TOP2A 2035/4885TOP2B 1896/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | NISCH 3115/4885TOP2A 2285/4885TOP2B 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.